Nektar Therapeutics

Nektar Flags Lilly’s Miscalculations in Rezpeg Atopic Dermatitis Trials
BioSpace
Mon, 08/7/23 - 10:51 am
Nektar Therapeutics
Eli Lill
Rezpeg
atopic dermatitis
After gathering enough Nektar, Lilly hands back rights to immunology med post-lupus fail
Fierce Biotech
Thu, 04/27/23 - 11:48 am
Eli Lilly
Nektar Therapeutics
Rezpeg
lupus
Fresh layoffs at Nektar Therapeutics as it drops lupus program after phase 2 disappointment
Biopharma Reporter
Thu, 04/20/23 - 10:47 am
Nektar Therapeutics
lupus
rezpegaldesleukin
layoffs
Rezpeg
After lupus setback, Nektar sticks with immunology but lays off 70% of hometown workforce
Fierce Biotech
Tue, 04/18/23 - 09:56 am
Nektar Therapeutics
reorganization
layoffs
Nektar's bitter pill: Phase 2 fail ends Lilly-partnered lupus program and prompts eczema rethink
Fierce Biotech
Fri, 02/24/23 - 09:27 am
Nektar Therapeutics
rezpegaldesleukin
clinical trials
lupus
Catalysts ahead for the smaller players
EP Vantage
Wed, 12/21/22 - 11:19 am
89Bio
Altimmune
AnaptysBio
BioXcel Therapeutics
Calliditas Therapeutics
Eli Lilly
Esperion Therapeutics
Geron
Nektar Therapeutics
Oramed Pharmaceuticals
Pliant Therapeutics
Replimune
Selecta Biosciences
Swedish Orphan Biovitrum
Vera Therapeutics
Viking Therapeutics
Nektar and PureTech merger talks called off
Pharmaforum
Tue, 10/11/22 - 10:40 am
M&A
Nektar Therapeutics
PureTech
Nektar and Puretech make strange bedfellows
EP Vantage
Fri, 10/7/22 - 10:42 am
Nektar Therapeutics
PureTech Health
M&A
A Post-mortem on the Failed Nektar-BMS Partnership at ESMO
BioSpace
Mon, 09/12/22 - 10:51 am
ESMO
Bristol Myers Squibb
Nektar Therapeutics
Nektar guts workforce, weeks after $3.6B Bristol Myers immuno-oncology collaboration ends
Fierce Biotech
Mon, 04/25/22 - 10:53 pm
Nektar Therapeutics
layoffs
Bristol Myers Squibb
Bristol Myers scraps $2B Nektar partnership after trial failures
BioPharma Dive
Mon, 04/18/22 - 11:42 pm
Bristol Myers Squibb
Nektar Therapeutics
immunotherapy
Opdivo
kidney cancer
bladder cancer
BMS and Nektar Shutter Combination Cancer Development Program
BioSpace
Fri, 04/15/22 - 01:42 pm
Bristol Myers Squibb
Nektar Therapeutics
bladder cancer
renal cell carcinoma
bempegaldesleukin
BMS-Nektar's Opdivo combo fails phase 3 in upset to once-largest licensing deal in biotech history
Fierce Biotech
Mon, 03/14/22 - 10:24 am
Bristol Myers Squibb
Opdivo
Nektar Therapeutics
bempegaldesleukin
clinical trials
Propel fails to propel Nektar
EP Vantage
Mon, 11/8/21 - 10:48 am
Nektar Therapeutics
Merck
bempegaldesleukin
clinical trials
metastatic non-small cell lung cancer
Sanofi drops 'intriguing' data on rival to Bristol Myers' bempeg
Fierce Biotech
Fri, 04/9/21 - 10:37 am
Sanofi
solid tumors
Bristol Myers Squibb
Nektar Therapeutics
Synthorx
clinical trials
Nektar, stung by new investor lawsuit over IL-2 drug, secures $150M for Keytruda combo pivotal trial
Endpoints
Wed, 02/17/21 - 11:00 am
Nektar Therapeutics
Bristol-Myers Squibb
NKTR-214
Nektar sells off royalties on its 2 approved drugs for $150M in cash, redoubling focus on I-O candidates
Endpoints
Wed, 12/23/20 - 10:44 am
Nektar Therapeutics
Adynovate
Movantik
HealthCare Royalty Partners
Immuno-oncology combination for melanoma using Nektar drug boosts cell therapy in mice
Fierce Biotech
Fri, 01/31/20 - 12:11 pm
melanoma
Nektar Therapeutics
bempegaldesleukin
Nektar pulls NDA for pain drug after unanimous AdComm rejection
Fierce Biotech
Wed, 01/15/20 - 11:10 am
Nektar Therapeutics
opioids
FDA
oxycodegol
Rough Meeting Ahead Between Nektar Therapeutics and FDA Advisory Committee
Motley Fool
Mon, 01/13/20 - 11:42 pm
Nektar Therapeutics
FDA
oxycodegol
painkillers

Pages